$-0.51 EPS Expected for Intra-Cellular Therapies, Inc. (ITCI)

February 19, 2018 - By Marguerite Chambers

 $ 0.51 EPS Expected for Intra Cellular Therapies, Inc. (ITCI)
Investors sentiment increased to 2.77 in 2017 Q3. Its up 1.91, from 0.86 in 2017Q2. It increased, as 9 investors sold Intra-Cellular Therapies, Inc. shares while 21 reduced holdings. 45 funds opened positions while 38 raised stakes. 39.74 million shares or 30.25% more from 30.51 million shares in 2017Q2 were reported.
Blume Cap Inc holds 1,000 shares. Bnp Paribas Arbitrage holds 0% or 4,196 shares. Illinois-based First Midwest Savings Bank Trust Division has invested 0.36% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Point72 Asia (Hong Kong) Limited reported 978 shares stake. Bluecrest Mgmt holds 0.01% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) or 18,529 shares. Atwood Palmer Inc has 200 shares. Parallax Volatility Advisers L P holds 98,088 shares. California-based Gemmer Asset Management Limited Liability has invested 0.06% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Parametric Assoc Ltd Llc accumulated 14,954 shares or 0% of the stock. Voya Inv Mgmt has invested 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Panagora Asset Management holds 99,024 shares or 0.01% of its portfolio. 25,164 were reported by Metropolitan Life Com Ny. The New York-based Msd Prtnrs Lp has invested 0.01% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). American International Group owns 22,635 shares. Gam Holdings Ag holds 0.02% or 30,700 shares.

Since September 29, 2017, it had 3 insider buys, and 9 insider sales for $10.92 million activity. The insider LERNER RICHARD A sold 7,000 shares worth $105,630. On Wednesday, January 3 Davis Robert E sold $17,394 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) or 1,115 shares. 258,065 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares with value of $4.00 million were bought by ALAFI CAPITAL CO LLC. Another trade for 258,065 shares valued at $4.00M was bought by Alafi Christopher D. Shares for $4.00 million were bought by ALAFI MOSHE on Monday, October 2. Mates Sharon sold $115,438 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) on Monday, January 8.

Analysts expect Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report $-0.51 EPS on March, 7.They anticipate $0.13 EPS change or 20.31 % from last quarter’s $-0.64 EPS. After having $-0.53 EPS previously, Intra-Cellular Therapies, Inc.’s analysts see -3.77 % EPS growth. The stock decreased 0.15% or $0.03 during the last trading session, reaching $19.97. About 486,573 shares traded or 10.56% up from the average. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has declined 68.76% since February 19, 2017 and is downtrending. It has underperformed by 85.46% the S&P500.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Ratings Coverage

Among 11 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. Intra-Cellular Therapies had 36 analyst reports since August 6, 2015 according to SRatingsIntel. On Monday, September 25 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Piper Jaffray maintained it with “Hold” rating and $14.0 target in Wednesday, August 23 report. The firm earned “Market Perform” rating on Thursday, September 29 by JMP Securities. RBC Capital Markets maintained the shares of ITCI in report on Friday, November 6 with “Outperform” rating. On Thursday, September 29 the stock rating was downgraded by SunTrust to “Neutral”. SunTrust upgraded the shares of ITCI in report on Wednesday, November 8 to “Buy” rating. Cantor Fitzgerald maintained Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) rating on Thursday, September 7. Cantor Fitzgerald has “Buy” rating and $29.0 target. The company was upgraded on Friday, August 7 by Zacks. The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has “Buy” rating given on Wednesday, August 23 by Cantor Fitzgerald. The firm has “Neutral” rating by Ladenburg Thalmann given on Tuesday, May 2.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company has market cap of $1.09 billion. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. It currently has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

More notable recent Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) news were published by: Globenewswire.com which released: “Intra-Cellular Therapies Expands Its Executive Team with the Appointment of Dr …” on November 13, 2017, also Businesswire.com with their article: “Newman Ferrara LLP Announces Corporate Governance Investigation of Intra …” published on January 10, 2018, Globenewswire.com published: “Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone …” on November 20, 2017. More interesting news about Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) were released by: Globenewswire.com and their article: “Intra-Cellular Therapies to Present at the 36th Annual JP Morgan Healthcare …” published on January 02, 2018 as well as Globenewswire.com‘s news article titled: “Intra-Cellular Therapies Announces Positive Regulatory Update On Schizophrenia …” with publication date: August 23, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: